

# Scifinder (lung cancer)

SciFinder - Explore References - Open PCMan 2007 Combo

Research Topic: lung cancer

Publication Year(s): 2011

Document Type(s):  Book,  Journal,  Review

Language(s):  English

Author Name: Last \* First Middle

SciFinder - Research Topic Candidates - Open PCMan 2007 Combo

Welcome peiyu lin | Sign Out

Research Topic "lung cancer" with limiters

2 Topics 1 Selected

Research Topic Candidates	References
<input checked="" type="checkbox"/> 6867 references were found containing "lung cancer" as entered.	6867
<input type="checkbox"/> 13261 references were found containing the concept "lung cancer".	13261

Get References

Contact Us | Copyrights and Trademarks  
Copyright © 2011 American Chemical Society. All Rights Reserved.

完成

SciFinder - Reference Answer Set - Open PCMan 2007 Combo

https://scifinder.cas.org/scifinder/view/scifinder/scifinder:Explore.jsf

1. Chemotherapy as first-line therapy for advanced non-small cell lung cancer  
 By Hirsch, Fred R.; Kabbinnavar, Fairouz; Eisen, Tim; Martins, Renato; Schnell, Fredrick M.; Dziadzuszko, Rafal; Richardson, Katherine; Richardson, Frank; Wacker, Bret; Sternberg, David W.; et al  
 From Journal of Clinical Oncology (2011), 29(29), 3948. | Language: English, Database: CAPLUS

2. Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data  
 Full Text  
 By Gusnanto, Arief; Wood, Henry M.; Pawitan, Yudi; Rabbitts, Pamela; Berri, Stefano  
 From Bioinformatics (2011), 28(1), 40-47. | Language: English, Database: CAPLUS  
 Motivation: Comparison of read depths from next-generation sequencing between cancer and normal cells makes the estn. of copy no. alteration (CNA) possible, even at very low coverage. However, estg. CNA from patients' tumor samples poses considerable challenges due to infiltration with normal cells and aneuploid cancer genomes. Here we provide a method that corrects contamination with normal cells and adjusts for genomes of different sizes so that the actual copy no. of each region can be estd. Results: The procedure consists of several steps. First, we identify the multi-modality of the d...

3. Critical role of plectin in anti-migration potential of curcumin  
 Full Text  
 By Ha, Young Ran; Choi, Yong Wook; Lee, Sang Joon  
 From Food Science and Biotechnology (2011), 20(6), 1615-1624. | Language: English, Database: CAPLUS  
 Plectin, a linker protein that organizes the cytoskeleton, is crit. for cell migration and wound healing. It is specifically expressed in epithelial cells, muscles, and other tissues. Numerous studies have shown that curcumin (diferuloylmethane) has anti-cancer potential. Curcumin can inhibit cancer cell migration and invasion through various signaling pathways. In this study, the down-regulation of plectin expression by siRNA was obsd. to induce the migration and invasion of human breast and lung cancer cell lines. Interestingly, the down-regulation of plectin expression by siRNA reverse...

4. Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer  
 Full Text  
 By Wang, Fang; Guo, Gui-fang; Qiu, Hui-juan; Chen, Xu-xian; Hu, Pi-li; Zhou, Fei-fei; He, Wen-zhuo; Zhang, Bei; Xia, Liang-ping  
 From Clinical Oncology and Cancer Research (2011), 8(4), 235-241. | Language: English, Database: CAPLUS  
 Objective Data on the efficacy profiles of pemetrexed monotherapy and pemetrexed plus platinum combination therapy in the non-first-line setting for patients with advanced non-small cell lung cancer (NSCLC) are limited, and previous studies have reported contradictory results. This study investigated and compared the efficacy and toxicity profiles of these two regimens to provide a broader understanding of their dynamics. Methods Previously treated patients with advanced and/or recurrent NSCLC who received pemetrexed monotherapy or pemetrexed plus platinum combination therapy between Jan. 1, 2006, and Dec. 31, 2009, at Sun Yat-sen University Cancer Center were evaluated. The primary endpoint of this study was progression-free survival (PFS), whereas the secondary endpoints were overall response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Survival was analyzed using the Kaplan-Meier method. Univariate anal. was performed to identify the factors potentially influencing OS, and chi-square anal. was carried out to compare ORR and DCR. Results Forty-six patients with advanced and/or recurrent NSCLC were analyzed; of these patients, 25 were given pemetrexed monotherapy and 21 received pemetrexed plus platinum combination therapy. The following correspond to the rates recorded for the pemetrexed monotherapy group and the pemetrexed plus platinum group: median PFS, 1.97 and 2.3 mo (P=0.565); median OS, 30.93 and 30.33 mo (P=0.877); ORR, 8% (2/25) and 9.5% (2/21) (P=0.857); and DCR, 32% (8/25) and 57.1% (12/21) (P=0.09). Univariate anal. revealed that no factor was correlated with OS from NSCLC (P>0.05 for all). Gastrointestinal toxicity in the pemetrexed plus platinum group was modestly higher than that in the pemetrexed monotherapy group (P=0.034), but other adverse events were similar between the groups. Conclusion Compared with pemetrexed monotherapy, pemetrexed plus platinum combination therapy causes more gastrointestinal toxicities and does not exhibit improved efficacy, in terms of ORR, DCR, PFS, and OS, in the non-first-line setting for NSCLC. However, further research with a higher patient population is necessary to validate this finding.

Rosell Rafael 33  
 Spitz Margaret R 32  
 Pao William 29  
 Wang Wei 29  
 Wistuba Ignacio I 28  
 Brennan Paul 26  
 Salgia Ravi 26  
 Yang Pan Chyr 26  
 Mishima Michiaki 25  
 Kiura Katsuyuki 24

Show More

Categorize  
 More detailed analysis based on CAS indexing  
 Categorize

SciFinder - Pemetrexed mono... - Open PCMan 2007 Combo

https://scifinder.cas.org/scifinder/view/scifinder/scifinder:Explore.jsf

Return

4. Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer

By: Wang, Fang; Guo, Gui-fang; Qiu, Hui-juan; Chen, Xu-xian; Hu, Pi-li; Zhou, Fei-fei; He, Wen-zhuo; Zhang, Bei; Xia, Liang-ping

Objective Data on the efficacy profiles of pemetrexed monotherapy and pemetrexed plus platinum combination therapy in the non-first-line setting for patients with advanced non-small cell lung cancer (NSCLC) are limited, and previous studies have reported contradictory results. This study investigated and compared the efficacy and toxicity profiles of these two regimens to provide a broader understanding of their dynamics. Methods Previously treated patients with advanced and/or recurrent NSCLC who received pemetrexed monotherapy or pemetrexed plus platinum combination therapy between Jan. 1, 2006, and Dec. 31, 2009, at Sun Yat-sen University Cancer Center were evaluated. The primary endpoint of this study was progression-free survival (PFS), whereas the secondary endpoints were overall response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Survival was analyzed using the Kaplan-Meier method. Univariate anal. was performed to identify the factors potentially influencing OS, and chi-square anal. was carried out to compare ORR and DCR. Results Forty-six patients with advanced and/or recurrent NSCLC were analyzed; of these patients, 25 were given pemetrexed monotherapy and 21 received pemetrexed plus platinum combination therapy. The following correspond to the rates recorded for the pemetrexed monotherapy group and the pemetrexed plus platinum group: median PFS, 1.97 and 2.3 mo (P=0.565); median OS, 30.93 and 30.33 mo (P=0.877); ORR, 8% (2/25) and 9.5% (2/21) (P=0.857); and DCR, 32% (8/25) and 57.1% (12/21) (P=0.09). Univariate anal. revealed that no factor was correlated with OS from NSCLC (P>0.05 for all). Gastrointestinal toxicity in the pemetrexed plus platinum group was modestly higher than that in the pemetrexed monotherapy group (P=0.034), but other adverse events were similar between the groups. Conclusion Compared with pemetrexed monotherapy, pemetrexed plus platinum combination therapy causes more gastrointestinal toxicities and does not exhibit improved efficacy, in terms of ORR, DCR, PFS, and OS, in the non-first-line setting for NSCLC. However, further research with a higher patient population is necessary to validate this finding.

Indexing  
 Pharmacology (Section 1)

Tags  
 0 Tags | Edit Tags

Source  
 Clinical Oncology and Cancer Research  
 Volume 8  
 Issue 4  
 Pages 235-241  
 Journal; Online Computer File  
 2011  
 CODEN: COCRCF  
 ISSN: 1674-5361  
 DOI: 10.1007/s11805-011-0587-3

Company/Organization  
 State Key Laboratory of Oncology in South China  
 Guangzhou 510060

Accession Number  
 2011:1683997  
 CAPLUS

Publisher  
 Tianjin Medical University Cancer Institute and Hospital

Language  
 English

藉著這堂課學會了基本操作，對於以後打報告找資料來說相當實用(學校難得供給學生這麼好的資源)！唯一美中不足的是，它只能同時容納 2 人登入使用，相當的不方便！！

# Innovation(missile engine)

Thomson Innovation - Open PCMan 2007 Combo

Patent Search

Quick Search: Patents  Go ?

Patent Search

Fielded Search | Publication Number

1 Review Selected Collections: US Grant, US App, EP Grant, EP App, WO App

2 Enter Criteria:

Text Fields  ?

AND Title/Abstract/Claims  ?

Clear All Fields Add Field

Search

System Notices: None

THOMSON REUTERS

Copyright 2007-2011 THOMSON REUTERS

Privacy | Terms of Use | Feedback | Contact Us | Help

Thomson Innovation - Open PCMan 2007 Combo

Patent Result Set

Quick Search: Patents  Go ?

Patent Result Set 1,535 records found out of 18,395,623 searched (Display Limit 30,000)

Return to Search | Display & Sort Options

1 records selected

Save | Alert | Mark List | Download | Charts | Print

<input type="checkbox"/>	Publication Number	Publication Date
<input type="checkbox"/>	<a href="#">US8081106B2</a>	2011-12-20
<input type="checkbox"/>	<a href="#">Title: Target ranging using information from two objects</a>	
<input type="checkbox"/>	<a href="#">US8079308B1</a>	2011-12-20
<input type="checkbox"/>	<a href="#">Title: Ramjet engine incorporating a tubular structure and a missile propelled by a ramjet engines of this type</a>	
<input type="checkbox"/>	<a href="#">US8066474B1</a>	2011-11-29
<input type="checkbox"/>	<a href="#">Title: Variable guide vane actuator</a>	
<input type="checkbox"/>	<a href="#">US8066218B2</a>	2011-11-29
<input type="checkbox"/>	<a href="#">Title: Anti-missile defense suite</a>	
<input checked="" type="checkbox"/>	<a href="#">US8056319B2</a>	2011-11-15
<input type="checkbox"/>	<a href="#">Title: Combined cycle missile engine system</a>	
<input type="checkbox"/>	<a href="#">US8055394B2</a>	2011-11-08

Displaying 1 - 10 of 1535 Page 1 of 154

Go to Page:  Go Display: 10 Records per page

System Notices: None

THOMSON REUTERS

Thomson Innovation - Facebook - Mozilla Firefox - LC-5 - 小畫家 上午 05:01



Thomson Innovation - Open PCMan 2007 Combo

連線 (C) 編輯 (E) 選項 (V) BBS最愛 (B) Web最愛 (A) 紀錄 (Y) ANSI編輯 (H) 工具 (T) 說明 (H)

http://www.thomsoninnovation.com/ip-innovation/recordView.do?pageOffset=4&recordCount=5&parentId=null&totalRec...

Patent Record View - US8056319B2

### Record View: Patent US8056319B2

Add to Work File | Mark Record | Watch Record | Download | Print

#### Quick View

**DWPI Title ?**  
Insensitive combined cycle **missile** propulsion system has rocket nozzle to exhaust combustion products resulting from combustion of fuel and oxidizer contained in respective sections of **missile**

**Original Title ?**  
Combined cycle **missile engine** system

**Abstract ?**  
An insensitive combined cycle **missile** propulsion system includes a solid fuel contained within a first section of the **missile**, a liquid oxidizer contained within a second section of the **missile** and a solid oxidizer contained within a third section of said **missile**. A first conduit has a first valve communicating the fuel and the oxidizer and a second conduit, spatially removed from the first conduit, has a second valve communicating the fuel and the oxidizer. An inlet system for delivering atmospheric oxygen for combustion with the fuel rich gases generated within the **missile** and a nozzle exhausts combustion products that result from combustion of the fuel, the liquid and solid oxidizers, and air.

**First Claim ?**  
1. An insensitive combined cycle **missile** propulsion system comprising:

Record 5 of 1535

完成

#### Images

Image 1/6

FIG. 1

1 2 3 4

Mark and Next

這程式對於將來走研究(發明)路線的人，非常有助，可以先得知有沒有人已經先申請專利了，免得白忙一場；而且它還可以以另類的圖表表示出哪一塊領域，別人涉足的較多，可以避開那些大廠商所謂的兵家必爭之地，在別的地區展露頭角。